PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
The estimated revenue has increased from the previous period.
-1.93M
The estimated EBITDA has decreased from the previous period.
-1.38
The estimated EPS has increased from the previous period.
-41.62M
The estimated net income has decreased from the previous period.
-1.93M
The estimated EBIT has decreased from the previous period.
358.54M
The estimated SG&A expenses have increased from the previous period.
Analyze DCF forecasts for the company and compare them with competitors.
1.14M
Revenue has increased from the previous period.
No Data
No DCF data available for this metric in the selected year.
-24.44M
EBITDA has decreased from the previous period.
-2136.36%
EBITDA margin has decreased from the previous period.
-24.96M
EBIT has decreased from the previous period.
-2182.17%
EBIT margin has decreased from the previous period.
524.00K
Depreciation has increased from the previous period.
77.83M
Total cash has increased from the previous period.
6803.23%
Cash percentage has increased from the previous period.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
5.54M
Accounts payable has increased from the previous period.
483.83%
Payables percentage has increased from the previous period.
-133.00K
Capital expenditure has decreased from the previous period.
-11.63%
CapEx percentage has increased from the previous period.
4.99%
WACC is unchanged from the previous period.
5.02%
Cost of equity is unchanged from the previous period.
4.08%
Cost of debt is unchanged from the previous period.
-0.23
Beta is unchanged from the previous period.
30.07M
Diluted shares outstanding is unchanged from the previous period.
1.57M
Total debt is unchanged from the previous period.
49.31M
Total equity is unchanged from the previous period.
50.89M
Total capital is unchanged from the previous period.
3.09%
Debt weighting is unchanged from the previous period.
96.91%
Equity weighting is unchanged from the previous period.
-24.77M
EBIAT has decreased from the previous period.
-23.19M
UFCF has decreased from the previous period.
2.00%
Long-term growth rate is unchanged from the previous period.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Net debt is unchanged from the previous period.
71.33M
Equity value is unchanged from the previous period.
2.37
Equity value per share is unchanged from the previous period.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Higher upside than AGEN's upside of 58.32%.
Buy
Equal to AGEN's analyst recommendation of Buy.